22 research outputs found
DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma
Full text linkTreatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Full text linkHighly-Purified Aspergillus Fumigatus Specific T-Cells as a Potential Treatment Option of Invasive Aspergillosis.
No full textPolymorphisms in the Genes Encoding Chemokine Receptor 5, Interleukin-10, and Monocyte Chemoattractant Protein 1 Contribute to Cytomegalovirus Reactivation and Disease after Allogeneic Stem Cell Transplantation
No full textWe analyzed 90 polymorphisms in 17 genes related to immune function for association with human cytomegalovirus (HCMV) reactivation and disease in patients after allogeneic stem cell transplantation. We found relevant markers (i) in CCR5 and IL-10 genes conferring a higher risk for the development of HCMV disease and (ii) in the MCP1 gene associated with HCMV reactivation. Testing of high-risk patients for the presence of these single-nucleotide polymorphisms might be useful for individualizing antiviral prophylaxis
Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01-09 Study (ClinicalTrials.gov Identifier: NCT00949364)
No full text
Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG)
No full textPomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01-09 Study (ClinicalTrials.gov Identifier: NCT00949364)
No full text
